Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 917

Similar articles for PubMed (Select 11695246)

1.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
2.

Nonsteroidal anti-inflammatory drugs for treatment of acute gout.

van Durme CM, Wechalekar MD, Landewé RB.

JAMA. 2015 Jun 9;313(22):2276-7. doi: 10.1001/jama.2015.1881.

PMID:
26057289
3.

Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.

Anwar A, John Anwar I, Delafontaine P.

Trends Cardiovasc Med. 2015 Mar 12. pii: S1050-1738(15)00079-1. doi: 10.1016/j.tcm.2015.03.006. [Epub ahead of print] Review.

PMID:
25956433
4.
5.

[Cardiovascular safety of non-steroidal anti-inflammatory drugs].

Møllersen MV, Norgård H, Spigset O, Slørdal L.

Tidsskr Nor Laegeforen. 2015 Mar 24;135(6):542-6. doi: 10.4045/tidsskr.14.1269. eCollection 2015 Mar 24. Norwegian.

6.

The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.

Balmaceda CM.

Postgrad Med. 2015 Jan;127(1):51-6. doi: 10.1080/00325481.2015.998593.

PMID:
25584932
7.

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review.

Asghar W, Jamali F.

Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.

PMID:
25515365
8.

How to mechanistically explain the CONDOR study data.

Spies CM, Stemmler E, Buttgereit F.

Med Hypotheses. 2015 Jan;84(1):14-9. doi: 10.1016/j.mehy.2014.11.007. Epub 2014 Nov 15.

PMID:
25433956
9.

COX-2 Inhibitors and Gastric Cancer.

Wang Z, Chen JQ, Liu JL.

Gastroenterol Res Pract. 2014;2014:132320. doi: 10.1155/2014/132320. Epub 2014 Oct 12. Review.

10.

Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors.

Ranger GS.

Anticancer Res. 2014 Nov;34(11):6277-82. Review.

PMID:
25368225
11.
13.

Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.

Kim HS, Kim T, Kim MK, Suh DH, Chung HH, Song YS.

J Cancer Prev. 2013 Jun;18(2):123-34. Review.

14.

Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects.

Stepensky D, Rimon G.

Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):41-52. doi: 10.1517/17425255.2014.971010. Epub 2014 Oct 13.

PMID:
25307725
15.
16.

Preferential Cyclooxygenase 2 Inhibitors as a Nonhormonal Method of Emergency Contraception: A Look at the Evidence.

Weiss EA, Gandhi M.

J Pharm Pract. 2014 Aug 3. pii: 0897190014544795. [Epub ahead of print]

PMID:
25092603
17.

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.

Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN.

Invest New Drugs. 2014 Dec;32(6):1105-12. doi: 10.1007/s10637-014-0144-z. Epub 2014 Aug 3.

PMID:
25085205
18.

COX inhibitors for the treatment of migraine.

Silberstein SD, Stirpe JC.

Expert Opin Pharmacother. 2014 Sep;15(13):1863-74. doi: 10.1517/14656566.2014.937704. Epub 2014 Jul 10. Review.

PMID:
25010639
19.

Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative.

Bavry AA, Thomas F, Allison M, Johnson KC, Howard BV, Hlatky M, Manson JE, Limacher MC.

Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):603-10. doi: 10.1161/CIRCOUTCOMES.113.000800. Epub 2014 Jul 8.

PMID:
25006185
20.

Risk of upper gastrointestinal bleeding from different drug combinations.

Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Kuipers EJ, van der Lei J, Sturkenboom MC.

Gastroenterology. 2014 Oct;147(4):784-792.e9; quiz e13-4. doi: 10.1053/j.gastro.2014.06.007. Epub 2014 Jun 14.

PMID:
24937265
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk